171 related articles for article (PubMed ID: 17363184)
1. Why G3139 works poorly in cancer trials but might work well against HIV.
Parris GE
Med Hypotheses; 2007; 69(3):537-40. PubMed ID: 17363184
[TBL] [Abstract][Full Text] [Related]
2. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
3. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
4. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
5. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK
Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046
[TBL] [Abstract][Full Text] [Related]
7. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
8. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
Wacheck V; Krepler C; Strommer S; Heere-Ress E; Klem R; Pehamberger H; Eichler HG; Jansen B
Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
12. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.
Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA
Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468
[TBL] [Abstract][Full Text] [Related]
13. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
14. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L
Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061
[TBL] [Abstract][Full Text] [Related]
15. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
Chi KC; Wallis AE; Lee CH; De Menezes DL; Sartor J; Dragowska WH; Mayer LD
Breast Cancer Res Treat; 2000 Oct; 63(3):199-212. PubMed ID: 11110054
[TBL] [Abstract][Full Text] [Related]
16. Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide.
Wiedenmann N; Koto M; Raju U; Milas L; Mason KA
Invest New Drugs; 2007 Oct; 25(5):411-6. PubMed ID: 17492397
[TBL] [Abstract][Full Text] [Related]
17. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.
Lacy J; Loomis R; Grill S; Srimatkandada P; Carbone R; Cheng YC
Int J Cancer; 2006 Jul; 119(2):309-16. PubMed ID: 16477627
[TBL] [Abstract][Full Text] [Related]
18. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
Klasa RJ; Gillum AM; Klem RE; Frankel SR
Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
[TBL] [Abstract][Full Text] [Related]
19. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.
Zhang X; Koh CG; Yu B; Liu S; Piao L; Marcucci G; Lee RJ; Lee LJ
Pharm Res; 2009 Jun; 26(6):1516-24. PubMed ID: 19291371
[TBL] [Abstract][Full Text] [Related]
20. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.
Lai JC; Benimetskaya L; Khvorova A; Wu S; Hua E; Miller P; Stein CA
Mol Cancer Ther; 2005 Feb; 4(2):305-15. PubMed ID: 15713901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]